CN105849109B - 取代的氧代吡啶衍生物 - Google Patents

取代的氧代吡啶衍生物 Download PDF

Info

Publication number
CN105849109B
CN105849109B CN201480071585.4A CN201480071585A CN105849109B CN 105849109 B CN105849109 B CN 105849109B CN 201480071585 A CN201480071585 A CN 201480071585A CN 105849109 B CN105849109 B CN 105849109B
Authority
CN
China
Prior art keywords
hydrogen
mmol
group
represented
represent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480071585.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105849109A (zh
Inventor
S.勒里希
A.希利施
J.施特拉斯布格
S.海特迈尔
M.V.施密特
K-H.施莱默
A.特施蒂根
A.布希米勒
C.格德斯
M.舍费尔
H.泰勒
E.希梅内斯努内斯
H.希罗克
J.克拉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN105849109A publication Critical patent/CN105849109A/zh
Application granted granted Critical
Publication of CN105849109B publication Critical patent/CN105849109B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201480071585.4A 2013-10-30 2014-10-28 取代的氧代吡啶衍生物 Expired - Fee Related CN105849109B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13190940 2013-10-30
EP13190940.0 2013-10-30
EP14186078 2014-09-24
EP14186078.3 2014-09-24
PCT/EP2014/073132 WO2015063093A1 (de) 2013-10-30 2014-10-28 Substituierte oxopyridin-derivate

Publications (2)

Publication Number Publication Date
CN105849109A CN105849109A (zh) 2016-08-10
CN105849109B true CN105849109B (zh) 2018-01-23

Family

ID=51795642

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480071585.4A Expired - Fee Related CN105849109B (zh) 2013-10-30 2014-10-28 取代的氧代吡啶衍生物

Country Status (7)

Country Link
US (1) US9765070B2 (https=)
EP (1) EP3063150B1 (https=)
JP (1) JP6368367B2 (https=)
CN (1) CN105849109B (https=)
CA (1) CA2928867A1 (https=)
ES (1) ES2659045T3 (https=)
WO (1) WO2015063093A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3197889B1 (de) 2014-09-24 2018-08-01 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
US10414731B2 (en) 2014-09-24 2019-09-17 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
EP3197891B1 (de) 2014-09-24 2018-11-21 Bayer Pharma Aktiengesellschaft Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
US10077265B2 (en) 2014-09-24 2018-09-18 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
EP3197872B1 (de) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft (2h)-2-oxopyridine als faktor xia-inhibitoren zur behandlung von thrombotischen erkrankungen
CA2979937A1 (en) * 2015-03-19 2016-09-22 Bayer Pharma Aktiengesellschaft Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
EP3344618A1 (de) 2015-09-04 2018-07-11 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3371162B1 (en) 2015-10-29 2022-01-26 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
WO2018039094A1 (en) 2016-08-22 2018-03-01 Merck Sharp & Dohme Corp. Pyridine-1-oxide derivatives and their use as factor xia inhibitors
BR112019003557A2 (pt) 2016-08-31 2019-05-21 Jiangsu Hengrui Medicine Co., Ltd. derivados de oxopicolinamida, método de preparação dos mesmos e uso farmacêutico dos mesmos
CA3091528A1 (en) 2018-02-27 2019-09-06 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of oxopicolinamide derivative and preparation method therefor
EP3765459A1 (en) 2018-03-13 2021-01-20 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
EP3774796B1 (en) 2018-04-10 2022-04-27 Bayer Pharma Aktiengesellschaft A substituted oxopyridine derivative
EP3793559A1 (en) * 2018-05-17 2021-03-24 Bayer Aktiengesellschaft Substituted dihydropyrazolo pyrazine carboxamide derivatives
EP3822264A4 (en) 2018-07-02 2021-11-10 Jiangsu Hengrui Medicine Co., Ltd. CRYSTALLINE FORMS OF AN OXYPYRIDINE AMIDE DERIVATIVE AND THEIR PREPARATION PROCESS
WO2020127508A1 (en) 2018-12-21 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
CN113474348A (zh) 2018-12-21 2021-10-01 拜耳公司 取代的氧代吡啶衍生物
DK4031547T3 (da) 2019-09-18 2024-09-09 Takeda Pharmaceuticals Co Plasmakallikreininhibitorer og anvendelser deraf
EP4031245A1 (en) 2019-09-18 2022-07-27 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
CN113135929B (zh) * 2020-01-17 2024-04-19 江西济民可信集团有限公司 呋喃并吡啶酮酰胺化合物及其制备方法和用途
CN113358792B (zh) * 2021-06-23 2023-02-24 北京亚宝生物药业有限公司 一种医药物质的hplc含量分析方法
CN116283908A (zh) * 2023-03-10 2023-06-23 合肥工业大学 一种n-芳香甲基吡啶酮类衍生物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042273A2 (en) * 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
CN101137412A (zh) * 2005-01-13 2008-03-05 布里斯托尔-迈尔斯·斯奎布公司 用作凝血因子Xla抑制剂的取代的二芳基化合物
GB2497806A (en) * 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US9732085B2 (en) * 2011-12-21 2017-08-15 Ono Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor Xia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042273A2 (en) * 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
CN101137412A (zh) * 2005-01-13 2008-03-05 布里斯托尔-迈尔斯·斯奎布公司 用作凝血因子Xla抑制剂的取代的二芳基化合物
GB2497806A (en) * 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Progress curve analysis of the kinetics with which blood coagulation factor XIa is inhibited by protease nexin-2;Joseph M. Scandura et al.;《Biochemistry》;19971231;第36卷(第2期);第412-420页 *

Also Published As

Publication number Publication date
CN105849109A (zh) 2016-08-10
US20160272637A1 (en) 2016-09-22
CA2928867A1 (en) 2015-05-07
WO2015063093A1 (de) 2015-05-07
US9765070B2 (en) 2017-09-19
EP3063150B1 (de) 2017-11-22
JP2016535031A (ja) 2016-11-10
ES2659045T3 (es) 2018-03-13
JP6368367B2 (ja) 2018-08-01
EP3063150A1 (de) 2016-09-07

Similar Documents

Publication Publication Date Title
CN105849109B (zh) 取代的氧代吡啶衍生物
CN105555767B (zh) 取代的氧代吡啶衍生物及其作为因子xia/血浆的用途
CN106687458B (zh) 取代的氧代吡啶衍生物
CN105164122B (zh) 取代的氧代吡啶衍生物及其在治疗心血管病症方面的用途
US10138236B2 (en) Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
US10071995B2 (en) Substituted oxopyridine derivatives
US10167280B2 (en) Substituted oxopyridine derivatives
EA036208B1 (ru) Замещенные производные оксопиридина
US10077265B2 (en) Substituted oxopyridine derivatives
US20180250280A1 (en) Substituted oxopyridine derivatives
US10414731B2 (en) Substituted oxopyridine derivatives
JP2018509426A (ja) 血栓症の治療のための因子ＸＩａ阻害剤としてのオキソピリジン誘導体
HK1227852A1 (en) Substituted oxopyridine derivatives
HK1237777A1 (en) Substituted oxopyridine derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1227852

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1227852

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180123